NCT04895202

Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study

Swiss Study of the Impact of Mayzent (Siponimod) on Secondary Progressive Multiple Sclerosis Patients in a Long-term Non-interventional Study

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 8 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a national, prospective, multicenter, non-interventional (observational) study with the aim to describe the impact of Siponimod treatment in a real-world SPMS population in Switzerland who are treated with Siponimod as per Swiss label.

Detailed description

Primary data will be collected during an observational period of three years of Siponimod treatment. Additionally, medical history of participants will be collected including EDSS, MRI outcomes, relapses and previous medication to allow the estimation of Siponimod treatment effects on an individual basis. It is planned to include an optional blood draw for a later biomarker analysis.

Conditions

• Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity

Interventions

Type	Name	Description
OTHER	Siponimod	Prospective observational cohort study. There is no treatment allocation. Patients administered siponimod as by swiss label, that have started before inclusion of the patient into the study will be enrolled.

Timeline

• Start date: 2021-11-19
• Primary completion: 2022-12-20
• Completion: 2022-12-20
• First posted: 2021-05-20
• Last updated: 2023-08-29

Locations

6 sites across 1 country: Switzerland